From paper to the cloud

The author also describes the benefits of a cloud platform in terms of sharing between different research and development teams.
The focus of the development of an approved gene therapy is on adeno-associated virus (AAV)-based gene therapies for the treatment of patients affected by haemophilia, Huntington's disease and other severe genetic disorders. This uses a modular and validated cloud platform. But before moving to a cloud-based platform, paper-based workflows make it difficult to track test results and collaborate across teams and locations. This is how many life sciences companies feel, as digitisation is not progressing very quickly, especially in research and development (R&D) departments. Read here the article.